IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CORRADINI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 21.613
AS - Asia 15.880
NA - Nord America 13.270
SA - Sud America 1.181
OC - Oceania 214
AF - Africa 185
Continente sconosciuto - Info sul continente non disponibili 22
Totale 52.365
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.836
CN - Cina 9.036
DE - Germania 6.226
GB - Regno Unito 5.663
IT - Italia 2.846
SG - Singapore 2.061
SE - Svezia 1.592
HK - Hong Kong 1.111
RU - Federazione Russa 1.110
BR - Brasile 846
IN - India 840
IE - Irlanda 720
FR - Francia 662
JP - Giappone 629
TR - Turchia 587
KR - Corea 548
NL - Olanda 530
UA - Ucraina 437
FI - Finlandia 401
ES - Italia 374
CA - Canada 314
ID - Indonesia 251
AU - Australia 199
EU - Europa 192
VN - Vietnam 191
CH - Svizzera 169
DK - Danimarca 165
PL - Polonia 148
CO - Colombia 130
BE - Belgio 117
AT - Austria 105
GR - Grecia 86
MX - Messico 79
PK - Pakistan 67
TH - Thailandia 62
AR - Argentina 60
TW - Taiwan 60
BD - Bangladesh 52
CZ - Repubblica Ceca 48
IL - Israele 48
SA - Arabia Saudita 48
PH - Filippine 42
PT - Portogallo 40
IQ - Iraq 38
EG - Egitto 33
ZA - Sudafrica 33
PE - Perù 31
UZ - Uzbekistan 31
IR - Iran 30
NO - Norvegia 30
CL - Cile 29
JO - Giordania 29
RO - Romania 28
MA - Marocco 26
HU - Ungheria 25
MY - Malesia 25
UY - Uruguay 23
VE - Venezuela 23
EC - Ecuador 20
AZ - Azerbaigian 19
HR - Croazia 16
NZ - Nuova Zelanda 15
KE - Kenya 14
SC - Seychelles 14
TN - Tunisia 14
BG - Bulgaria 9
KZ - Kazakistan 9
PY - Paraguay 9
RS - Serbia 9
SK - Slovacchia (Repubblica Slovacca) 9
BO - Bolivia 8
DZ - Algeria 8
GE - Georgia 8
CI - Costa d'Avorio 7
EE - Estonia 7
GH - Ghana 7
LB - Libano 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AL - Albania 6
JM - Giamaica 6
KW - Kuwait 6
LT - Lituania 6
MK - Macedonia 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
BA - Bosnia-Erzegovina 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
OM - Oman 5
PA - Panama 5
SI - Slovenia 5
SN - Senegal 5
SY - Repubblica araba siriana 5
GT - Guatemala 4
MD - Moldavia 4
NG - Nigeria 4
NP - Nepal 4
BY - Bielorussia 3
CM - Camerun 3
ET - Etiopia 3
Totale 52.483
Salva come PNG Salva come JPEG
Città #
Beijing 5.277
Southend 4.902
Frankfurt am Main 4.680
Singapore 1.297
Chandler 1.237
Milan 1.052
Hong Kong 981
Seattle 850
Dublin 712
Princeton 705
Wilmington 683
Ashburn 651
Fairfield 518
Council Bluffs 495
Ann Arbor 424
Nanjing 364
Woodbridge 335
Jacksonville 306
Dearborn 304
Redmond 295
Houston 274
Des Moines 268
Bengaluru 264
Shanghai 255
Santa Clara 206
Mountain View 201
Cambridge 193
Columbus 191
Tokyo 186
New York 184
The Dalles 175
Redwood City 173
Berlin 172
Jakarta 172
Andover 156
Guangzhou 156
Sakarya 156
Boardman 153
Los Angeles 138
Toronto 138
Jinan 137
Munich 135
Seoul 123
Sunnyvale 119
Somerville 118
Serra 114
Tianjin 113
Bogotá 110
Cangzhou 108
Hangzhou 104
Helsinki 104
Shenyang 104
São Paulo 99
Hanover 93
Rome 92
Nanchang 91
London 87
Nuremberg 83
Barcelona 82
Hebei 82
Warsaw 82
Brussels 77
Changsha 76
Chicago 74
Paris 72
Phoenix 70
Wuhan 70
Istanbul 65
San Diego 63
Vienna 63
Madrid 62
Sydney 60
Fuzhou 59
Chengdu 58
Dong Ket 57
Kiez 54
Jiaxing 52
Falls Church 51
Hefei 51
Turku 50
Kunming 48
Zhengzhou 47
Athens 46
Turin 46
Melbourne 45
Moscow 44
Hyderabad 43
Rochester 41
Amsterdam 40
Bologna 40
Duncan 39
Mumbai 39
Boston 38
Fremont 35
Haikou 35
Eitensheim 34
Naples 34
Osaka 34
Bitonto 33
Brisbane 33
Totale 34.037
Salva come PNG Salva come JPEG
Nome #
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant 4.588
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 1.763
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial 1.157
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations 928
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas 795
Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients 671
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial 557
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 487
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas 451
Autologous transplantation and maintenance therapy in multiple myeloma 411
Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects 351
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression 339
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups 310
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR 295
Non-invasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study 282
Genomic patterns of progression in smoldering multiple myeloma 255
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 253
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma 251
SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias 247
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 236
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma : Three-year Follow-up of CASTOR 235
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG) 225
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia : early assessment can predict long-term outcome after reduced intensity allogeneic transplantation 218
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 216
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells 216
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients 213
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 212
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 210
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma 209
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 204
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning : a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo 203
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era 203
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients 203
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBC 202
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 201
Genomic landscape and chronological reconstruction of driver events in multiple myeloma 198
Brief chemoimmunotherapy rituximab ®-FND +/- R maintenance is effective and safe newly diagnosed follicular lymphoma elderly patients : an intergruppo italiano linfomi (IIL) randomized trial 196
Non-myeloablative allografting for newly diagnosed multiple myeloma : the experience of the Gruppo Italiano Trapianti di Midollo. 193
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 192
Brief chemoimunotherapy with rituximab (R)- Find ± R maintenance as first treatment in adevanced follicular lymphoma (FL) in elderly : preliminary analysis of a prospective randomized trial 191
Brief chemoimmunoterapy rituximab (R)-FND ± R maintenance as first line treatment in elderly patients with advanced follicular lymphoma (FL) : preliminary analysis of a prospective randomized IIL trial 190
Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation 188
Analysis of the genomic lanscape of multiple myeloma highlights novel candidate prognostic markers and disease subgroups 186
Long term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies 184
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 183
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 183
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 183
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 181
Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma 181
A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes 180
Analysis of different biological factors in patients affected by peripheral T-cell lymphomas not otherwise specified: GATA-3 expression is associated to refractory disease and poor outcome 178
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas : pre-transplant disease status and histotype heavily influence outcome 177
Dioxin exposure of human CD34(+) hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects 177
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 174
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50 172
Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications 172
T-Cell lymphomas 171
Long-term outcome of ric-allo SCT for myeloma 170
Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation 170
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients 170
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment 169
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 169
Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components 168
GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes 168
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 168
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 167
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines 167
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 167
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT 165
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma 163
Gene expression profile of human normal hematopoietic cells exposed to dioxin 161
Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting : Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes 160
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 160
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 159
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation : Life-threating Features Within the Early Post-engraftment Phase 158
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates 157
Rituximab (R) maintenance versus observation after short term chemoimmunotherapy R-Find as first line treatment in elderly patients with advanced follicular lymphoma (FL) : updated results and safety of the maintenance of an Intergruppo Italiano Linfomi (ILL) randomized trial 157
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation 157
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation 156
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study 156
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab : a 20-year retrospective follow-up study in patients with lymphoma 155
Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients 155
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 154
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements 154
Identification of Clonal Igh Gene Rearrangements By High-Throughput Sequencing of Cell Free DNA in Multiple Myeloma Patients 154
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk 153
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 152
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed 151
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas : long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 151
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 150
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis : the superior disease control of R-HDS does not translate into an overall survival advantage 150
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs 150
Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma 150
A prospective phase II study on tandem autografting-nonmyeloablative allografting for newly diagnosed myeloma : final results of the Gruppo Italiano Trapianto Midollo Osseo 149
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 148
N- and K-ras oncogenes in plasma cell dyscrasias 148
Romidepsin in relapsed/refractory T-cell lymphomas : Italian experience and results of a named patient program 148
The genomic landscape of structural variations and complex events in multiple myeloma 147
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation 147
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma 146
Totale 28.601
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.325
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.325
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219.474 288 283 458 162 416 432 277 307 626 392 5.422 411
2021/20224.885 417 241 292 271 359 279 452 400 525 408 343 898
2022/20235.771 687 483 486 577 599 1.054 163 356 539 175 415 237
2023/20247.375 240 317 263 310 906 371 858 807 431 775 1.030 1.067
2024/202511.792 845 1.253 779 1.123 780 511 453 1.109 673 916 1.097 2.253
2025/2026730 730 0 0 0 0 0 0 0 0 0 0 0
Totale 54.781